Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- EXTX.OL
- Price
- 3.06
- Stock movement up
- +- (%)
- Company name
- Exact Therapeutics AS
- Exchange
- (OL ,
- Currency
- NOK )
- Sector
- Healthcare >Biotechnology
- Market cap
- 193.59M
- Ent value
- 164.23M
- Price/Sales
- -
- Price/Book
- 4.29
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- 42.87%
- 1 year return
- -49.00%
- 3 year return
- -42.97%
- 5 year return
- -
- 10 year return
- -
Last updated: 2025-04-12
DIVIDENDS
EXTX.OL does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | 4.29 |
| EV to Sales | - |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 63.26M |
| EPS (TTM) | -1.12 |
| FCF per share (TTM) | -1.09 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 0.00 |
| Gross profit (TTM) | 0.00 |
| Operating income (TTM) | -36.75M |
| Net income (TTM) | -36.00M |
| EPS (TTM) | -1.12 |
| EPS (1y forward) | - |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 45.57M |
| Net receivables | 0.00 |
| Total current assets | 55.90M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 13.68M |
| Total assets | 61.32M |
| Accounts payable | 7.21M |
| Short/Current long term debt | 0.00 |
| Total current liabilities | 15.49M |
| Total liabilities | 16.22M |
| Shareholder's equity | 45.10M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -34.55M |
| Capital expenditures (TTM) | 314.44K |
| Free cash flow (TTM) | -34.86M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -79.81% |
| Return on Assets | -58.70% |
| Return on Invested Capital | -79.81% |
| Cash Return on Invested Capital | -77.29% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 3.06 |
| Daily high | 3.06 |
| Daily low | 3.00 |
| Daily Volume | 0K |
| All-time high | 40.90 |
| 1y analyst estimate | - |
| Beta | 0.16 |
| EPS (TTM) | -1.12 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| EXTX.OL | S&P500 | |
| Current price drop from All-time high | -92.52% | -12.89% |
| Highest price drop | -92.66% | -56.47% |
| Date of highest drop | 7 Apr 2025 | 9 Mar 2009 |
| Avg drop from high | -60.38% | -11.07% |
| Avg time to new high | 300 days | 12 days |
| Max time to new high | 1186 days | 1805 days |
COMPANY DETAILS
Marketcap
193.59M
Marketcap category
Small-cap
Description
EXACT Therapeutics AS, a clinical stage biopharmaceutical company, develops a technology platform for targeted therapeutic enhancement, Acoustic Cluster Therapy (ACT). The ACT is an approach to ultrasound-mediated, targeted drug enhancement with the potential to amplify the clinical utility of a range of therapeutic agents across various indications, including within oncology and brain diseases. The company's ACT platform is under Phase I clinical trial for treatment of liver metastases; and pre-clinical studies for pancreatic, glioblastoma, and immunotherapy diseases, as well as CNS diseases and gene therapy. EXACT Therapeutics AS has a collaboration with GE Healthcare for the development of a ready-to-use formulation of Sonazoid for ultrasound imaging and therapy; and with Agenus Inc. to develop proprietary immune checkpoint inhibitors in combination with EXACT's Acoustic Cluster Technology, in pancreatic cancer. The company was formerly known as Phoenix Solutions AS. EXACT Therapeutics AS was founded in 2012 and is based in Oslo, Norway.
Employees
12
Website
Investor relations
-
SEC filings
CEO
Country
Norway
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
Cordance Medical, a pioneer in non-invasive medical technologies for brain disease treatment, and EXACT Therapeutics (Euronext Growth: EXTX), a clinical-stage precision medicine company, are pleased t...
January 28, 2025